
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 6, 2011

EXACTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)

Florida	0-28240	59-2603930
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2320 NW 66th Court
Gainesville, Florida 32653**

(Address of Principal Executive Office)

Registrant's telephone number, including area code (352) 377-1140

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 1.01. Entry into a Material Definitive Agreement.

On December 6, 2011, Exactech, Inc., a Florida corporation (the “Company”), entered into an amendment (the “Amendment”) to its Deferred Prosecution Agreement (the “DPA”) with the United States Attorney’s Office for the District of New Jersey (the “USAO”) that extends the term of the DPA for three months, ending on March 8, 2012. As previously reported, Exactech entered into the DPA in December 2010 in connection with the resolution of the investigation commenced by the USAO in December 2007 into the Company’s consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States. In accordance with the DPA, an independent monitor was appointed to review and evaluate Exactech’s compliance with its obligations under the DPA, and the Company agreed to extend the term of the DPA, at the request of the USAO, in order to allow the monitor additional time to further test the implementation of compliance systems. The USAO has not alleged any breach by Exactech of any of the terms of the DPA, and, other than extending its term, the Amendment makes no other changes to the DPA. The Amendment is subject to approval by the United States District Court for the District of New Jersey.

The foregoing description of the Amendment is only a summary and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On December 7, 2011, the Company issued a press release announcing its entry into the Amendment. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the Company under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
10.1	Amendment to Deferred Prosecution Agreement, dated December 6, 2011, between Exactech, Inc. and the United States Attorney’s Office for the District of New Jersey.
99.1	Press Release, dated December 7, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXACTECH, INC.

Date: December 7, 2011

By: /s/ Joel C. Phillips
Joel C. Phillips
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
10.1	Amendment to Deferred Prosecution Agreement, dated December 6, 2011, between Exactech, Inc. and the United States Attorney's Office for the District of New Jersey.
99.1	Press Release, dated December 7, 2011.

Addendum to the Deferred Prosecution Agreement

1. Exactech, Inc. (“Exactech”), by its undersigned attorneys, pursuant to authority granted by its Board of Directors, and the United States Attorney’s Office for the District of New Jersey (the “Office”), enter into this Addendum to the Deferred Prosecution Agreement (the “Addendum”).
2. Exactech and the Office agree to extend the term of the Deferred Prosecution Agreement currently in effect between Exactech and the Office (the “DPA”) by a period of three (3) months, from December 8, 2011, to March 8, 2012. Except for these terms expressly addressed herein, all other terms and conditions of the DPA will continue to be in full force and effect until March 8, 2012.
3. Paragraphs 1 and 4 of the DPA are hereby amended to substitute “fifteen (15) months” for “twelve (12) months.”
4. Exactech and the Office agree to modify the date upon which the next report from the Monitor is due from on or before December 7, 2011, to on or before February 8, 2012.
5. The Office agrees to move on December 6, 2011, for an Order, in the form attached as Exhibit A, further continuing the proceedings in United States v. Exactech, Inc., Criminal No. 10-837 (GEB), through and including March 8, 2012.

AGREED TO:

/s/ William Petty
William Petty, M.D.
Chairman of the Board of Directors
and Chief Executive Officer
Exactech, Inc.

December 5, 2011
Date

/s/ J. Gilmore Childers
J. Gilmore Childers
Attorney for the United States, Acting Under
Authority Conferred by 28 U.S.C. § 515

December 6, 2011
Date



227 ATLANTIC BLVD | KEY LARGO, FL 33037 | TEL: 305.451.1888
 CHRYSLER BUILDING | 405 LEXINGTON AVE, 26TH FL | NEW YORK, NY 10174 | TEL: 212.541.2465



WWW.HAWKASSOCIATES.COM
 IR CONTACT: JULIE MARSHALL

Exactech Announces Agreement with U.S. Attorney's Office

Voluntarily Extends Term of Deferred Prosecution Agreement for Three Months

GAINESVILLE, Fla. – December 7, 2011 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it agreed to enter into an amendment to its Deferred Prosecution Agreement (DPA) with the United States Attorney's Office for the District of New Jersey (USAO) that extends the term of the DPA for three months, ending on March 8, 2012. As previously announced, Exactech entered into the DPA in December 2010 in connection with the resolution of the investigation commenced by the USAO in December 2007 into the Company's consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States. In accordance with the DPA, an independent monitor was appointed to review and evaluate Exactech's compliance with its obligations under the DPA, and the Company agreed to extend the term of the DPA, at the request of the USAO, in order to allow the monitor additional time to further test the implementation of compliance systems. The USAO has not alleged any breach by Exactech of any of the terms of the DPA, and, other than extending its term, the amendment makes no other changes to the DPA.

A copy of the amendment to the DPA has been posted to the Company's website and filed with the U.S. Securities and Exchange Commission as an exhibit to the Company's Current Report on Form 8-K.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company's products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Investor contacts
 Jody Phillips
 Chief Financial Officer
 352-377-1140

Julie Marshall or Frank Hawkins
 Hawk Associates
 305-451-1888
 E-mail: exactech@hawkassociates.com